Combination chemotherapy with 4'Demethylepipodophyllotoxin 9-(4,6-0-ethylidene-beta-D-glucopyranoside), VP 16-213 (NSC 141540) in L1210 leukemia.
D000818:Animals; D000970:Antineoplastic Agents / Q000633:toxicity; D002330:Carmustine / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D003609:Dactinomycin / Q000627:therapeutic use; D003630:Daunorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000627:therapeutic use* / Q000633:toxicity; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D007939:Leukemia L1210 / Q000188:drug therapy*; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D051379:Mice; D008811:Mice, Inbred DBA; D011034:Podophyllotoxin / Q000627:therapeutic use*; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D003561:Cytarabine; D003609:Dactinomycin; D014750:Vincristine; D005047:Etoposide; D003520:Cyclophosphamide; D015122:Mercaptopurine; D011034:Podophyllotoxin; D005472:Fluorouracil; D002330:Carmustine; D008727:Methotrexate; D003630:Daunorubicin